Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab

Last updated: August 22, 2025
Sponsor: Daewoong Pharmaceutical Co. LTD.
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Williams Syndrome

Vascular Diseases

Stress

Treatment

Rosuvastatin, Olmesartan Medoxomil

Clinical Study ID

NCT05411887
DWOS_OLO_004
  • Ages > 19
  • All Genders

Study Summary

The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the clinical trials, and to evaluate variables that affect treatment effectiveness.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. men and women over the age of 19

  2. Patients who signed a written consent form to participate in the study

  3. Patients who are eligible for Olostar tablet prescription according to domesticpermission

Exclusion

Exclusion Criteria:

  1. A person who falls under "2. Do not administer to the following patients" among theprecautions for use in the user manual

  2. Patients in hospital (hospitals only; nursing care facilities can be recruited)

  3. A person who has been administered the study target drug or is being administered atthe time of recruitment within 6 months based on the date of the study contract

Study Design

Total Participants: 2845
Treatment Group(s): 1
Primary Treatment: Rosuvastatin, Olmesartan Medoxomil
Phase:
Study Start date:
June 20, 2022
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Severance Hospital

    Seoul,
    Korea, Republic of

    Site Not Available

  • Severance Hospital

    Seoul 1835848,
    South Korea

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.